Kodiak Sciences Inc. – NASDAQ:KOD

Add to watchlist

$9.34

-0.64

-6.41%

Market closed

Open in 2 days

+232.67%

month

+232.67%

quarter

+214.83%

year

Market Cap	494.92M
Enterprise value	N/A

P/E	-0.76
EV/Sales	N/A
EV/EBITDA	0.57
Price/Sales	N/A
Price/Book	N/A
PEG ratio	N/A
EPS	-4.43

Revenue	N/A
EBITDA	-230.80M
Income	-232.75M
Revenue Q/Q	N/A
Revenue Y/Y	N/A

Profit margin	0%
Oper. margin	0%
Gross margin	0%
EBIT margin	0%
EBITDA margin	N/A

Get more financial ratios!

Every financial ratio you might need
10 years history
Forward ratios (Analysts estimates)

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Kodiak Sciences Stock Forecast

M Q Y

Last Year

$11

Potential upside: 17.77%

Analysts Price target
Financials & Ratios estimates

Kodiak Sciences Inc. (NASDAQ:KOD): Profit margin
Jun 2023	0	-80.18M
Sep 2023	0	-50.00M
Dec 2023	0	-59.51M
Mar 2024	0	-43.03M

Kodiak Sciences Inc. (NASDAQ:KOD): Debt to assets
Jun 2023	589659000	251.18M	42.6%
Sep 2023	547652000	245.23M	44.78%
Dec 2023	479372000	213.59M	44.56%
Mar 2024	434759000	193.57M	44.52%

Kodiak Sciences Inc. (NASDAQ:KOD): Cash Flow
Jun 2023	-41.95M	103.84M	170K
Sep 2023	-32.76M	-226K	-12K
Dec 2023	-32.23M	-27.79M	-124K
Mar 2024	-39.6M	-166K	38K

Kodiak Sciences alternative data

Social Media

🎓 Academy: How impactful can social media data be in investment decisions

Kodiak Sciences Inc. (NASDAQ:KOD): Employee count
Aug 2023	115
Sep 2023	118
Oct 2023	118
Nov 2023	118
Dec 2023	116
Jan 2024	116
Feb 2024	116
Mar 2024	116
Apr 2024	116
May 2024	111
Jun 2024	107
Jul 2024	107

Kodiak Sciences
Hedge Funds Holdings Q1 2023

21.11% -58.71%

of KOD is owned by hedge funds

72 -59

hedge funds hold KOD stock

11.03M -30.70M

shares is hold by hedge funds

KOD hedge funds holdings changes

Kodiak Sciences
Insider Trading

Kodiak Sciences Inc. (NASDAQ:KOD): Insider trades (number of shares)
Period	Buy	Sel
Jun 2024	0	1558

Transaction	Date	Insider	Security	Shares	Price per share	Total value
Sale	12 Jun 2024	BORGESON JOHN A. officer: See Remarks officer: See Remarks	Common Stock	1,558	$2.92	$4,549
Option	11 Jun 2024	BORGESON JOHN A. officer: See Remarks officer: See Remarks	Common Stock	3,025	N/A	N/A
Option	11 Jun 2024	BORGESON JOHN A. officer: See Remarks officer: See Remarks	Restricted Stock Units	3,025	N/A	N/A
Sale	16 Jun 2023	EHRLICH JASON officer: See Rema..	Common Stock	2,258	$9.23	$20,841
Sale	16 Jun 2023	BORGESON JOHN A. officer: See Remarks officer: See Remarks	Common Stock	2,749	$9.23	$25,373
Option	15 Jun 2023	EHRLICH JASON officer: See Rema..	Common Stock	5,494	N/A	N/A
Option	15 Jun 2023	EHRLICH JASON officer: See Rema..	Restricted Stock Units	3,619	N/A	N/A
Option	15 Jun 2023	EHRLICH JASON officer: See Rema..	Restricted Stock Units	1,875	N/A	N/A
Option	15 Jun 2023	BORGESON JOHN A. officer: See Remarks officer: See Remarks	Common Stock	5,494	N/A	N/A
Option	15 Jun 2023	BORGESON JOHN A. officer: See Remarks officer: See Remarks	Restricted Stock Units	3,619	N/A	N/A

KOD insider trading transactions

Status	Patent	Filling date	Issue date
Application	Application Acryloyloxyethylphosphorylcholine Containing Polymer Conjugates And Their Preparation Filling date: 16 Dec 2021 Issue date: 31 Mar 2022	16 Dec 2021	31 Mar 2022
Application	Application HIGH MOLECULAR WEIGHT ZWITTERION-CONTAINING POLYMERS Filling date: 23 Aug 2021 Issue date: 30 Dec 2021	23 Aug 2021	30 Dec 2021
Application	Application ANTIBODIES AND CONJUGATES THEREOF Filling date: 8 Apr 2021 Issue date: 21 Oct 2021	8 Apr 2021	21 Oct 2021
Grant	Grant Utility: Butyrylcholinesterase zwitterionic polymer conjugates Filling date: 3 May 2019 Issue date: 27 Jul 2021	3 May 2019	27 Jul 2021
Grant	Grant Utility: Antibodies and conjugates thereof Filling date: 29 Dec 2016 Issue date: 20 Jul 2021	29 Dec 2016	20 Jul 2021
Application	Application METHODS OF TREATING AN EYE DISORDER Filling date: 9 Oct 2020 Issue date: 15 Apr 2021	9 Oct 2020	15 Apr 2021
Application	Application DUAL PDGF/VEGF ANTAGONISTS Filling date: 19 Feb 2020 Issue date: 20 Aug 2020	19 Feb 2020	20 Aug 2020
Application	Application FACTOR VIII ZWITTERIONIC POLYMER CONJUGATES Filling date: 4 Feb 2020 Issue date: 20 Aug 2020	4 Feb 2020	20 Aug 2020
Grant	Grant Utility: Factor VIII zwitterionic polymer conjugates Filling date: 8 Sep 2014 Issue date: 7 Jul 2020	8 Sep 2014	7 Jul 2020
Application	Application HIGH MOLECULAR WEIGHT ZWITTERION-CONTAINING POLYMERS Filling date: 31 Jan 2020 Issue date: 4 Jun 2020	31 Jan 2020	4 Jun 2020

Kodiak Sciences
Earnings Call Transcripts

Quarter	Transcript
Q4 2023 28 Mar 2024	Q4 2023 Earnings Call Transcript
Q1 2020 13 May 2020	Q1 2020 Earnings Call Transcript
Q3 2019 14 Nov 2019	Q3 2019 Earnings Call Transcript

KOD earnings call transcripts

Kodiak Sciences
Executives

Insider	Age	Compensation
Dr. Victor Perlroth M.D. (1973) Co-Founder, Chairman, Chief Executive Officer & Pres	52	$1,110,000
Dr. Jason S. Ehrlich M.D., Ph.D. (1976) Chief Medical Officer & Chief Devel. Officer	49	$812,260
Mr. John A. Borgeson CPA, M.B.A., MBA, CPA (1962) Senior Vice President, Chief Financial Officer & Sec.	63	$692,620

Kodiak Sciences
Latest News

Thursday, 26 December 2024
11:32	What Awaits These 4 Biotech Stocks That More Than Doubled in 2024	zacks.com
Tuesday, 10 December 2024
11:45	KOD Stock Up as Jefferies Upgrades Rating on Huge Pipeline Potential	zacks.com
Monday, 9 December 2024
12:33	Eye-Disease Focused Kodiak Sciences Is A Promising 'Turnaround Story For 2025': Analyst Upgrades Stock	benzinga.com
Monday, 25 November 2024
10:56	Kodiak Sciences Inc. (KOD) Just Flashed Golden Cross Signal: Do You Buy?	zacks.com
Friday, 15 November 2024
10:51	Kodiak Q3 Loss Narrower Than Expected, Pipeline Development in Focus	zacks.com
Thursday, 14 November 2024
16:01	Kodiak Sciences Announces Recent Business Highlights and Third Quarter 2024 Financial Results	prnewswire.com
Monday, 11 November 2024
06:15	Kodiak Sciences to Participate in Upcoming Investor Conferences	prnewswire.com
Monday, 14 October 2024
17:35	Kodiak Sciences to Present at Innovate Retina 2024	prnewswire.com
Thursday, 10 October 2024
11:06	Kodiak Counts on Tarcocimab Eye Disease Program Despite Setbacks	zacks.com
Monday, 23 September 2024
06:00	Kodiak Sciences to Host Investor R&D Day Today at 10:30am Eastern Time	prnewswire.com
Tuesday, 17 September 2024
16:05	Kodiak Sciences to Host Investor R&D Day on September 23, 2024 in New York City	prnewswire.com
Friday, 13 September 2024
12:31	Why Is Kodiak Sciences (KOD) Down 8.1% Since Last Earnings Report?	zacks.com
Friday, 16 August 2024
11:45	Kodiak (KOD) Q2 Loss Narrower Than Expected, Pipeline in Focus	zacks.com
Wednesday, 14 August 2024
16:01	Kodiak Sciences Announces Recent Business Highlights and Second Quarter 2024 Financial Results	prnewswire.com
Wednesday, 10 July 2024
13:00	All You Need to Know About Kodiak Sciences (KOD) Rating Upgrade to Buy	zacks.com
Thursday, 20 June 2024
09:25	Should You Hold Kodiak Sciences (KOD) Stock in Your Portfolio?	zacks.com
Friday, 14 June 2024
12:30	Why Is Kodiak Sciences (KOD) Down 26.2% Since Last Earnings Report?	zacks.com
Wednesday, 29 May 2024
16:36	Kodiak Sciences to Present at Upcoming Investor and Clinical Conferences	prnewswire.com
Thursday, 16 May 2024
13:56	Kodiak (KOD) Q1 Loss Narrower Than Expected, Pipeline in Focus	zacks.com
Wednesday, 15 May 2024
16:01	Kodiak Sciences Announces Recent Business Highlights and First Quarter 2024 Financial Results	prnewswire.com
Monday, 13 May 2024
19:32	Kodiak Sciences Announces Treatment of First Patients in Phase 3 GLOW2 Study of Tarcocimab Tedromer in Diabetic Retinopathy	prnewswire.com
Thursday, 2 May 2024
16:30	Kodiak Sciences Data at ARVO 2024 Highlight Depth of Early and Late-Phase Retina Pipeline including Advancements with High Drug-Antibody-Ratio Therapeutics Built on Kodiak's Antibody Biopolymer Conjugate (ABC) Platform	prnewswire.com
Thursday, 4 April 2024
13:11	Kodiak (KOD) Counts on Tarcocimab Program Despite Setbacks	Zacks Investment Research
Monday, 1 April 2024
13:00	Kodiak (KOD) Stock Falls on Q4 Earnings Miss, Pipeline in Focus	Zacks Investment Research
Thursday, 28 March 2024
20:57	Kodiak Sciences Inc. (KOD) Q4 2023 Earnings Call Transcript	Seeking Alpha
Tuesday, 26 March 2024
06:15	Kodiak Sciences to Report Fourth Quarter and Full-Year 2023 Financial Results and Host Business Updates Webcast on March 28, 2024	PRNewsWire
Thursday, 1 February 2024
12:56	TEVA Q4 Earnings and Revenues Surpass Estimates, Stock Up	Zacks Investment Research
Thursday, 4 January 2024
16:15	Kodiak Sciences to Present at the 42nd Annual J.P. Morgan Healthcare Conference	PRNewsWire
Tuesday, 21 November 2023
16:15	Kodiak Sciences to Present at the 6th Annual Evercore ISI HealthCONx Conference	PRNewsWire
Wednesday, 15 November 2023
09:02	Kodiak (KOD) Beats Q3 Earnings, Provides Pipeline Updates	Zacks Investment Research

Ideas & Opinions

Seeking Alpha 12 Jun 2025

EyePoint Stock: Retaining My 'Risky Buy' Call - Pivotal Data Due Early 2026
Seeking Alpha 7 Jul 2023

4D Molecular Therapeutics: A Complicated Story
Seeking Alpha 14 Nov 2022

Kodiak: Turnaround Strategy Has Shown Life Thus Far
Seeking Alpha 8 Aug 2022

Kodiak Sciences: All Eyes For A Sentiment Turnaround After Positive Beacon Results
Seeking Alpha 17 May 2022

Kodiak Sciences: Potential For Comeback After Trial Setback
Seeking Alpha 8 Mar 2022

Ocular Therapeutix: Transformative Year Ahead Full Of Important Milestones
Seeking Alpha 15 Feb 2022

Highlighting Kodiak Sciences: A Great Buy Here Ahead Of Phase 3 Wet AMD Data For KSI-301 This Quarter
Seeking Alpha 6 Jul 2021

Regenxbio: Suprachoroidal Data May Impress
Seeking Alpha 6 May 2021

Ocular Therapeutix: Catalysts Stacking
Seeking Alpha 22 Apr 2021

Ocular Therapeutix: Good Medicine, High Competition

Frequently Asked Questions (FAQ)

What's the price of Kodiak Sciences stock today?

One share of Kodiak Sciences stock can currently be purchased for approximately $9.34.
When is Kodiak Sciences's next earnings date?

Unfortunately, Kodiak Sciences's (KOD) next earnings date is currently unknown.
Does Kodiak Sciences pay dividends?

No, Kodiak Sciences does not pay dividends.
How much money does Kodiak Sciences make?

Kodiak Sciences has a market capitalization of 494.92M.
What is Kodiak Sciences's stock symbol?

Kodiak Sciences Inc. is traded on the NASDAQ under the ticker symbol "KOD".
What is Kodiak Sciences's primary industry?

Company operates in the Healthcare sector and Biotechnology industry.
How do i buy shares of Kodiak Sciences?

Shares of Kodiak Sciences can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Who are Kodiak Sciences's key executives?
Kodiak Sciences's management team includes the following people:
- Dr. Victor Perlroth M.D. Co-Founder, Chairman, Chief Executive Officer & Pres(age: 52, pay: $1,110,000)
- Dr. Jason S. Ehrlich M.D., Ph.D. Chief Medical Officer & Chief Devel. Officer(age: 49, pay: $812,260)
- Mr. John A. Borgeson CPA, M.B.A., MBA, CPA Senior Vice President, Chief Financial Officer & Sec.(age: 63, pay: $692,620)
Is Kodiak Sciences founder-led company?

Yes, Kodiak Sciences is a company led by its founder Dr. Victor Perlroth M.D..
How many employees does Kodiak Sciences have?

As Jul 2024, Kodiak Sciences employs 107 workers, which is 8% less then previous quarter.
When Kodiak Sciences went public?

Kodiak Sciences Inc. is publicly traded company for more then 6 years since IPO on 4 Oct 2018.
What is Kodiak Sciences's official website?

The official website for Kodiak Sciences is kodiak.com.
Where are Kodiak Sciences's headquarters?

Kodiak Sciences is headquartered at 1200 Page Mill Road, Palo Alto, CA.
How can i contact Kodiak Sciences?

Kodiak Sciences's mailing address is 1200 Page Mill Road, Palo Alto, CA and company can be reached via phone at +65 02810850.
What is Kodiak Sciences stock forecast & price target?

Based on 2 Wall Street analysts` predicted price targets for Kodiak Sciences in the last 12 months, the avarage price target is $11. The average price target represents a 17.77% change from the last price of $9.34.

Kodiak Sciences Inc.

kodiak.com

Exchange:

NASDAQ

Full time employees:

111

Industry:

Biotechnology

Sector:

Healthcare

Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is KSI-301, an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy. The company's preclinical stage product candidate includes KSI-501, a bispecific conjugate to treat retinal diseases with an inflammatory component; and KSI-601, a triplet inhibitor for the treatment of dry AMD. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto, California.

+65 02810850

1200 Page Mill Road
Palo Alto, CA 94304

CIK: 0001468748
ISIN: US50015M1099
CUSIP: 50015M109